Jesse Shefferman - 19 Jan 2023 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Role: CEO and President, Director
Signature: /s/ Mary Grendell, Attorney-In-Fact
Issuer symbol: TARA
Transactions as of: 19 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 20 Jan 2023, 15:00:14 UTC
Previous filing: 11 Jan 2023
Next filing: 27 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARA	Common Stock	Award	$0	+51,300	+5.9%	$0.000000	918,282	19 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARA	Stock Option (Right to Buy)	Award	$0	+307,500		$0.000000	307,500	19 Jan 2023	Common Stock	307,500	$3.02	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023.
F2	25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.